Trial Profile
A Randomized Phase II Study to Assess the Activity of TroVax (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA 5T4 (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Oxford BioMedica
- 29 Jul 2013 Results will be published in Cancer Immunology, Immunotherapy, in 2013, according to an Oxford BioMedica media release reporting highlights.
- 10 Oct 2012 Verified results data from the 27 enrolled patients will be presented at the first Immunotherapies and Cancer Vaccines Conference in December 2012.
- 10 Oct 2012 Status changed from recruiting to discontinued, as reported by Oxford BioMedica in a media release.